---
title: Publications
---

(Under construction)

## Recent

Mukhopadhyay, P., Ye, J., Anderson, K. M., Roychoudhury, S., Rubin, E. H., Halabi, S., & Chappell, R. J. (2022). Log-Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno-oncology Trials: A Systematic Review and Meta-analysis. JAMA oncology.

Anderson, K. M., Guo, Z., Zhao, J., & Sun, L. Z. (2022). A unified framework for weighted parametric group sequential design. Biometrical Journal.

Chen, T. Y., Zhao, J., Sun, L., & Anderson, K. M. (2021). Multiplicity for a group sequential trial with biomarker subpopulations. Contemporary Clinical Trials, 101, 106249.

Bautista, O., & Anderson, K. (2021). Sample Size Estimation and Power Analysis: Time to Event Data. In Handbook of Statistical Methods for Randomized Controlled Trials (pp. 275-300). Chapman and Hall/CRC.

Roychoudhury, S., Anderson, K. M., Ye, J., & Mukhopadhyay, P. (2021). Robust design and analysis of clinical trials with nonproportional hazards: a straw man guidance from a cross-pharma working group. Statistics in Biopharmaceutical Research, 1-15.

Lin, R. S., Lin, J., Roychoudhury, S., Anderson, K. M., Hu, T., Huang, B., ... & Working, C. P. N. P. H. (2020). Rejoinder to letter to the editor “The hazards of period specific and weighted hazard ratios”. Statistics in Biopharmaceutical Research, 12(4), 520.

Lin, R. S., Lin, J., Roychoudhury, S., Anderson, K. M., Hu, T., Huang, B., ... & Cross-Pharma Non-Proportional Hazards Working Group. (2020). Alternative analysis methods for time to event endpoints under nonproportional hazards: a comparative analysis. Statistics in Biopharmaceutical Research, 12(2), 187-198.

Tian, L., Jin, H., Uno, H., Lu, Y., Huang, B., Anderson, K. M., & Wei, L. J. (2020). On the empirical choice of the time window for restricted mean survival time. Biometrics, 76(4), 1157-1166.

León, L. F., Lin, R., & Anderson, K. M. (2020). On weighted log-rank combination tests and companion Cox model estimators. Statistics in Biosciences, 12(2), 225-245.

Turner, D. C., Kondic, A. G., Anderson, K. M., Robinson, A. G., Garon, E. B., Riess, J. W., ... & Stone, J. A. (2018). Pembrolizumab Exposure–Response Assessments Challenged by Association of Cancer Cachexia and Catabolic ClearancePembrolizumab PK/PD Confounding and Cancer Cachexia. Clinical Cancer Research, 24(23), 5841-5849.

Joseph, Richard W., et al. "Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab: Impact of Baseline Tumor Size on Outcomes in Melanoma." *Clinical Cancer Research* *24.20* (2018): 4960-4967.

Chen, Cong, et al. "A 2-in-1 adaptive phase 2/3 design for expedited oncology drug development." Contemporary clinical trials 64 (2018): 238-242.

## 1999

- Antman, E. M., Giugliano, R. P., Gibson, C. M., McCabe, C. H.,
Coussement, P., Kleiman, N. S., Vahanian, A., Adgey, A. J., Menown, I.,
Rupprecht, H.-J., et al. (1999). Abciximab facilitates the rate and
extent of thrombolysis: Results of the thrombolysis in myocardial
infarction (TIMI) 14 trial. *Circulation*, *99*(21), 2720–2732.

## 1997

- CAPTURE Investigators and others. (1997). Randomized
placebo-controlled trial of abciximab before and during coronary
intervention in refractory angina: The CAPTURE study. *Lancet*, *349*,
1429–1435.

- EPILOG Investigators. (1997). Platelet glycoprotein IIb/IIIa
receptor blockade and low-dose heparin during percutaneous coronary
revascularization. *New England Journal of Medicine*, *336*(24),
1689–1697.

- Topol, E. J., Ferguson, J. J., Weisman, H. F., Tcheng, J. E., Ellis,
S. G., Kleiman, N. S., Ivanhoe, R. J., Wang, A. L., Miller, D. P.,
Anderson, K. M., et al. (1997). Long-term protection from myocardial
ischemic events in a randomized trial of brief integrin *β*3
blockade with percutaneous coronary intervention. *JAMA*, *278*(6),
479–484.

## 1994

- EPIC Investigators. (1994). Use of a monoclonal antibody directed
against the platelet glycoprotein IIb/IIIa receptor in high-risk
coronary angioplasty. *New England Journal of Medicine*, *330*(14),
956–961.

- Topol, E., Califf, R., Weisman, H., Ellis, S., Tcheng, J., Worley,
S., Ivanhoe, R., George, B., Fintel, D., Weston, M., et al. (1994).
Randomised trial of coronary intervention with antibody against platelet
IIb/IIIa iritegrin for reduction of clinical restenosis: Results at six
months. *The Lancet*, *343*(8902), 881–886.

## 1993

- Ho, K., Anderson, K. M., Kannel, W. B., Grossman, W., & Levy, D.
(1993). Survival after the onset of congestive heart failure in
framingham heart study subjects. *Circulation*, *88*(1), 107–115.

## 1992

- Castelli, W. P., Anderson, K., Wilson, P. W., & Levy, D. (1992).
Lipids and risk of coronary heart disease the framingham study. *Annals
of Epidemiology*, *2*(1-2), 23–28.

## 1991

- Anderson, K. M., Odell, P. M., Wilson, P. W., & Kannel, W. B.
(1991). Cardiovascular disease risk profiles. *American Heart Journal*,
*121*(1), 293–298.

- Anderson, K. M., Wilson, P., Odell, P. M., & Kannel, W. B. (1991).
An updated coronary risk profile. A statement for health professionals.
*Circulation*, *83*(1), 356–362.

- Galderisi, M., Anderson, K. M., Wilson, P. W., & Levy, D. (1991).
Echocardiographic evidence for the existence of a distinct diabetic
cardiomyopathy (the framingham heart study). *The American Journal of
Cardiology*, *68*(1), 85–89.

- Lauer, M. S., Anderson, K. M., Kannel, W. B., & Levy, D. (1991).
The impact of obesity on left ventricular mass and geometry: The
framingham heart study. *JAMA*, *266*(2), 231–236.

## 1990

- D’Agostino, R. B., Lee, M.-L., Belanger, A. J., Cupples, L. A.,
Anderson, K., & Kannel, W. B. (1990). Relation of pooled logistic
regression to time dependent cox regression analysis: The framingham
heart study. *Statistics in Medicine*, *9*(12), 1501–1515.

- Levy, D., Labib, S. B., Anderson, K. M., Christiansen, J. C.,
Kannel, W. B., & Castelli, W. P. (1990). Determinants of sensitivity and
specificity of electrocardiographic criteria for left ventricular
hypertrophy. *Circulation*, *81*(3), 815–820.

- Levy, D., Garrison, R. J., Savage, D. D., Kannel, W. B., &
Castelli, W. P. (1990). Prognostic implications of echocardiographically
determined left ventricular mass in the framingham heart study. *New
England Journal of Medicine*, *322*(22), 1561–1566.

## 1988

- LEVY, D., ANDERSON, K. M., SAVAGE, D. D., KANNEL, W. B.,
CHRISTIANSEN, J. C., & Castelli, W. P. (1988). Echocardiographically
detected left ventricular hypertrophy: Prevalence and risk factors: The
framingham heart study. *Annals of Internal Medicine*, *108*(1), 7–13.

## 1987

- Anderson, K. M., Castelli, W. P., & Levy, D. (1987). Cholesterol
and mortality: 30 years of follow-up from the framingham study. *JAMA*,
*257*(16), 2176–2180.

- Levy, D., Savage, D. D., Garrison, R. J., Anderson, K. M., Kannel,
W. B., & Castelli, W. P. (1987). Echocardiographic criteria for left
ventricular hypertrophy: The framingham heart study. *The American
Journal of Cardiology*, *59*(9), 956–960.

- Levy, D., Anderson, K. M., Savage, D. D., Balkus, S. A., Kannel, W.
B., & Castelli, W. P. (1987). Risk of ventricular arrhythmias in left
ventricular hypertrophy: The framingham heart study. *The American
Journal of Cardiology*, *60*(7), 560–565.

## 1986

- Castelli, W. P., & Anderson, K. (1986). A population at risk:
Prevalence of high cholesterol levels in hypertensive patients in the
framingham study. *The American Journal of Medicine*, *80*(2), 23–32.
